10 results
The primary objective of this study is to measure whether αvβ3 integrin expression and tracer uptake values of 68Ga-DOTA-(RGD)2 change in patients with (recurrent) low-flow vascular malformations after embolization therapy.
Part 1 - To determine effects of different ianalumab doses on ALT normalization at Week 24 in patients with AIH who are incomplete responders or intolerant to standard therapy.Part 2 - To confirm the efficacy (biochemical and histological remission…
The key purpose of Safety lead in part of this study is to determine the maximum tolerable dose of anebumab ravtansine in combination with cisplatin for treatment of mesothelin-expressing cholangiocarcinoma, and similar for the combination with…
Main objective: - Evaluate the effect of itraconazole, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein (P-gp) inhibitor, on the safety and tolerability (including "thorough" electrocardiogram [ECG] assessment) and…
1.To monitor the safety and tolerability of racecadotril in combination with 111In-DOTA-MG112.To study in patients whether the neutral endopeptidase (NEP) inhibitor racecadotril improves the in vivo stability of the radiopeptide 111In-DOTA-MG11
The main objective of this study is to test the effects of combined SGLT1 and SGLT2 inhibition with sotagliflozin on hemoconcentration and plasma volume in patients with heart failure.
To compare the effect of eltrombopag and IVIG on the achievement of the platelet count threshold before and after surgery.
The primary objective is to demonstrate the efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-edotreotide to prolong progression freesurvival in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine…
This study is designed to demonstrate the CV and renal effects of sotagliflozin in patients with T2D, high CV risk, and moderate renal impairment. One of the major objectives of this study is to fulfill the regulatory mandate that any new therapy…
Primary: To characterize safety and tolerability of TNO155 and identify a recommended dose and regimen for future studies in adult patients with advanced solid tumors. And a recommended dose of TNO155 in combination with nazartinib in patients with…